Clinical outcomes of hepatitis c treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California

Digestive Diseases and Sciences

Volumn 58, Issue 12, 2013, Pages 3620-3625

  Rossaro, Lorenzo ^a   Torruellas, Cara ^a   Dhaliwal, Sandeep ^a   Botros, Jacqueline ^a   Clark, Guiselle ^a   Li, Chin Shang ^a   Minoletti, Mia M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis C; Interferon; Medically under served areas; Ribavirin; Rural communities; Telemedicine

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; AMBULATORY CARE; ANEMIA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DEPRESSION; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GROUP THERAPY; HEPATITIS C; HUMAN; INSOMNIA; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RURAL AREA; SIDE EFFECT; SOCIAL STATUS; TELECONSULTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CALIFORNIA; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; MALE; MEDICALLY UNDERSERVED AREA; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; TELEMEDICINE; TREATMENT OUTCOME;

EID: 84890122831     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2810-y     Document Type: Article

References (19)

1. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-278.
2. Daniels D. Surveillance for acute viral hepatitis - United States, 2007. Source: morbidity and mortality weekly report. CDC Surveillance Summ [1546-0738]. 2009;58:1-27.
3. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008;47:1128-1135.
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
5. Verna EC, Brown RS Jr. Hepatitis C and liver transplantation. Clin Liver Dis. 2006;10:919.
6. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant. 2008;8:958-976.
7. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Cost of hepatitis C. Arch Intern Med. 2001;161:22-31.
8. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1-39.
9. Rocca LG, Yawn BP, Wollan P, Kim WR. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med. 2004;2:116-124.
10. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther. 2007;25:1153-1162.
11. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
12. Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver related death. J Viral Hepat. 2004;11:148-156.
13. Poodard F, McCone J, Bacon B, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
14. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-1217.
15. Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract. 2002;51:135-140.
16. Rossaro L, Aoki C, Yuk J, Prosser C, Goforth J, Martinez F. The evaluation of patients with hepatitis C living in rural California via telemedicine. Telemed e-Health. 2008;14:1127-1129.
17. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Eng J Med. 2011;364:2199-2207.
18. Rossaro L, Tran TP, Cole SL, Nesbitt TS. Telemedicine: improving access to care of hepatitis C. Pract Gastroenterol. 2003;17:21-22.
19. Torruellas C, Rossaro CC, Li C-S, Rossaro L. The use of telemedicine for the management of hepatitis C & the California telehealth network, advances in telemedicine. In: Graschew G, ed. Applications in Various Medical Disciplines and Geographical Regions. InTech; 2011. ISBN: 978-953-307-161-9. doi: 10.5772/14451, modified).